A study on the methylation patterns of in patients with heart failure and its correlation with key clinical parameters.

OBJECTIVE

This study aimed to analyze the methylation pattern of deoxyribonucleic acid (CpG) sites in the _FA26 promoter region of patients with heart failure (HF) and explore the correlation between differential CpG methylation levels and various clinical parameters.

METHODS

Peripheral blood specimens were collected from 20 patients with HF and 20 healthy individuals. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry was used to identify and detect the CpG sites in the _FA26 promoter region. CpG methylation levels were compared between patients with HF and healthy controls and patients with HF with different levels of cardiac function.

RESULTS

The methylation level of _FA26_CpG_17.18 in patients with HF was significantly lower than that in the healthy control group ( = 0.0002). Among patients with HF and cardiac function levels of I/II and III/IV, methylation levels of _FA26_CpG_24.25.26.27 ( = 0.0168) were significantly lower in those with III/IV cardiac function compared to those with I/II cardiac function.

CONCLUSION

The methylation level of _FA26_CpG_17.18 is significantly reduced in patients with HF, and that of _FA26_CpG_24.25.26.27 is significantly decreased in patients with III/IV cardiac function. Variations in _FA26 methylation levels influence coagulation, liver and kidney functions, and routine blood indexes, including D-dimer, albumin, calcium, and hemoglobin. This study provides clinical evidence for the involvement of _FA26 methylation in the occurrence and development of HF and proposes novel targets for HF prevention and treatment.